New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
08:44 EDTHEBHemispherx reports evidence based clinical potential of IFN-alpha
Hemispherx Biopharma announced publication of an article entitled "Emergence of a novel drug resistant H7N9 influenza virus: Evidence based clinical potential of a natural IFN-alpha for infection control and treatment". H7N9 is a recently identified virus associated with high mortality in humans with the potential to emerge as an agent for a global pandemic. New cases of H7N9 have been very recently reported in China, Hong Kong and Taiwan. In vitro tests reported in the new article demonstrated that both oseltamivir and Alferon N have significant inhibitory effect on a neuraminidase inhibitor sensitive H7N9 influenza virus. In contrast, Alferon N, but not Tamiflu, had an inhibitory effect on the neuraminidase resistant Shanghai/1/H7N9 virus. According to the peer-reviewed article, "The novel avian H7N9 influenza virus has caused more than 130 human infections with 43 deaths in China. Because of the lack of existing immunity against H7 subtype influenza viruses in the human population and the absence of a licensed commercial vaccine, antiviral drugs are critical tools for the treatment of infection with this novel H7N9. Both M2-ion channel blockers and neuraminidase inhibitors are used as antiviral drugs for influenza infections of humans. The emerging H7N9 viruses are resistant to the M2-ion channel blockers because of a S31N mutation in the M2 protein; additionally, some H7N9 isolates have gained neuraminidase R292K substitution resulting in broad resistance to neuraminidase inhibitors. In this study we report that Alferon N can inhibit wild type and 292K H7N9 viruses replication in vitro. Since Alferon N is approved for clinical use, this would allow a rapid regulatory approval process for this drug under pandemic threat."
News For HEB From The Last 14 Days
Check below for free stories on HEB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:44 EDTHEBHemispherx Ampligen induces cross-reactive antibody formation
Subscribe for More Information
September 10, 2014
08:35 EDTHEBHemispherx expands Ebola collaborative research agreement with governments
Hemispherx Biopharma announced that it expanded its Collaborative Research Agreement to test Alferon, the only multi-species, natural alpha interferon, or IFN, commercially approved in the U.S. and Ampligen®, an experimental drug, to be evaluated against the deadly Ebola virus also under the DEA, or Data Exchange Agreement, Annex for Medical Preparedness and Bio-Defense Agreement between the Swiss Surgeon General and the US Department of Defense. The World Health Organization has warned that "The Ebola outbreak will affect more than 20,000 people in West Africa and might spread to more countries, indicating a clinical emergency all over the world."
September 8, 2014
08:43 EDTHEBHemispherx, USAMRIID to collaborate in studying Alferon, Ampligen
Hemispherx Biopharma announced that the company and United States Army Medical Research Institute of Infectious Diseases, or USAMRIID, scientists have agreed to test Alferon, the only multi-species, natural alpha interferon, or IFN, commercially approved in the U.S. and Ampligen, an experimental drug, to be evaluated against the deadly Ebola virus, which has been and remains a major focus of efforts at USAMRIID, a unit of the Department of Defense responsible for medical biological defense research. A key component of innate immune responses is activation of the Toll-like receptors, or TLRs. TLR3 activation by dsRNA is an essential response element to viral infection. Block TLR3 activation and an essential element of the innate immune response is disarmed. Ampligen, Poly I:Poly C12U was designed as an IFN inducer and has demonstrated antiviral activity in a wide variety of DNA and RNA viruses in pre-clinical testing. Replenishing an Ebola patient's natural interferon with Alferon and restoring that patient's innate immune response by Ampligen's overcoming the Ebola blocking mechanisms could potentially reduce the morbidity and mortality of Ebola virus disease.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use